TD Cowen raised the firm’s price target on Genpact to $36 from $35 and keeps a Hold rating on the shares. The firm said they noted no discernible change in underlying demand further traction in strategic initiatives is evident and drove healthy 2Q outperformance across the board.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on G: